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Introduction
A growing body of clinical and laboratory evidence indicates 
that inflammation plays a crucial role in atherosclerosis.1,2 It 
has been demonstrated that coronary artery stenting induces 
a systemic inflammatory response.3–6 This inflammation has 
also been linked to in-stent restenosis and in-stent throm-
bosis.7 It has been suggested that inflammation by activating 
platelet activation play a central role in in-stent restenosis and 
in-stent thrombosis.8
Current guidelines recommend the administration of 
dual antiplatelet therapy consisting of aspirin and a  platelet 
P2Y12 adenosine diphosphate (ADP) receptor antagonist 
(thienopyridine) to all patients undergoing percutaneous 
coronary intervention (PCI) to prevent recurrent ischemia 
and stent thrombosis.9,10 Both clopidogrel and prasugrel are 
noncompetitive thienopyridine antagonists of P2Y12, which 
inhibit the ability of ADP to induce platelet aggregation.11 
The Trial to Assess Improvement in Therapeutic Outcomes by 
Optimizing Platelet Inhibition with Prasugrel – Thrombolysis 
in Myocardial Infarction (TRITON-TIMI 38) study is the 
largest study evaluating the efficacy of prasugrel compared 
with clopidogrel in patients with acute coronary syndromes 
undergoing PCI.12 However, the primary end point of this 
study was the composite of death resulting from cardiovascular 
Prasugrel Results in Higher Decrease in High-Sensitivity 
C-Reactive Protein Level in Patients Undergoing  
Percutaneous Coronary Intervention Comparing to  
Clopidogrel
shokoufeh hajsadeghi1, Mandana Chitsazan2, Mitra Chitsazan3, negar salehi4,5, ahmad amin5, 
arash amin Bidokhti6, nima Babaali6, armin Bordbar6, Maral hejrati7 and samar Moghadami7
1Associate Professor of Cardiology, Department of Cardiology, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. 
2Research Fellow, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3Research Fellow, Rajaei Cardiovascular Medical and 
Research Center, Iran University of Medical Sciences, Tehran, Iran. 4Michigan State University, Sparrow Health System, East Lansing, MI, 
USA. 5Assistant Professor of Cardiology, Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, 
Iran. 6Cardiology Resident, Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. 7Research 
Fellow, Tehran University of Medical Sciences, Tehran, Iran.
AbstrAct
ObjectIves: A growing body of clinical and laboratory evidence indicates that inflammation plays a crucial role in atherosclerosis. In the present 
study, we compared the effects of clopidogrel and prasugrel on high-sensitivity C-reactive protein (hs-CRP) in patients undergoing percutaneous coronary 
intervention (PCI).
MethOds: The present randomized, double-blind clinical trial included 120 patients who underwent PCI. Eligible patients were randomly assigned 2:1 
to one of the two groups: 80 patients in the first group received clopidogrel (Plavix®; loading dose and maintenance dose of 300 and 75 mg daily, respec-
tively) and 40 patients in the second group received prasugrel (Effient®; loading dose and maintenance dose of 60 and 10 mg, respectively) for 12 weeks. The 
hs-CRP levels between baseline and 12th week were compared.
results: Of the 120 patients, 69 patients (57.5%) were male. Pretreatment hs-CRP level was statistically comparable in clopidogrel (median, 15.10 mg/dL; 
interquartile range [IQR], 9.62–23.75 mg/dL) and prasugrel groups (median, 18 mg/dL; IQR, 14.25–22 mg/dL; P = 0.06). Patients taking clopidogrel 
showed a significant reduction in hs-CRP level compared with the baseline values (P , 0.001). Prasugrel administration also resulted in a significant reduc-
tion in hs-CRP level (P , 0.001). A significant 73% overall reduction in the hs-CRP level was seen with prasugrel compared with 39% overall reduction 
in hs-CRP level with clopidogrel (P = 0.002).
cOnclusIOn: Prasugrel seems to be superior to clopidogrel in the reduction of hs-CRP in patients undergoing PCI.
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causes, nonfatal myocardial infarction, or nonfatal stroke, 
and the effects of clopidogrel and prasugrel on inflammatory 
markers were not studied.
Therefore, in the present study, we compared the anti-
inflammatory effects of clopidogrel and prasugrel in patients 
undergoing PCI, reflected as reduction in high-sensitivity 
C-reactive protein (hs-CRP).
Methods
Patient population. The present randomized, double-
blind clinical trial included 120 consecutive patients who 
underwent PCI at Rajaei Cardiovascular Medical and Research 
Center, Tehran, Iran, during April 2014 to December 2014. 
Patients were eligible for enrollment if they had undergone 
PCI with any of the indications mentioned below:
•	 planned PCI for stable angina or unstable angina/non-
ST elevation myocardial infarction (UA/NSTEMI), or
•	 planned PCI after medical treatment for ST-segment 
elevation myocardial infarction (STEMI), or
•	 primary PCI for STEMI.
UA was defined as the presence of symptoms at rest; or 
symptoms that have suddenly increased in frequency, severity, 
or duration; or had a change from the usual pattern of angina 
and did not respond to rest or nitroglycerin.13
Key exclusion criteria included increased risk of major 
bleeding, treatment with thienopyridines, history of myocar-
dial infarction or coronary intervention and/or revascular-
ization, clinically assessed Killip class II/III heart failure or 
cardiogenic shock, liver failure, acute/chronic kidney failure 
with serum creatinine of more than 2.5 mg/dL, and plate-
let count of ,100.000/mm3. Patients with malignancies, 
chronic inflammatory diseases, or infectious disorders were 
also excluded. The primary end point of this analysis was to 
assess the effects of a 12-week administration of prasugrel 
versus clopidogrel on hs-CRP serum level in patients under-
going PCI. The secondary end points were to compare the 
effects of prasugrel versus clopidogrel on hs-CRP in special 
subgroups of participants. The study was conducted accord-
ing to the most recent amendments to the Declaration of 
Helsinki. The study protocol was approved by institutional 
review board, and written informed consent was obtained 
from all patients.
Antiplatelet administration. Eligible patients were 
randomly assigned to 2:1 to one of the two groups: 
80 patients in the first group received a 300 mg loading 
dose of clopidogrel (Plavix®) 24 hours before the planned 
PCI or immediately before the procedure in patients with 
primary PCI, followed by a 75 mg daily maintenance dose 
for up to 12 weeks; 40 patients in the second group were 
administered a 60 mg loading dose of prasugrel (Effient®) 
24 hours before the planned PCI or immediately before the 
procedure in patients with primary PCI followed by a 10 mg 
daily maintenance dose for up to 12 weeks. Concomitant 
with  clopidogrel or  prasugrel administration, all patients 
received an 80 mg loading dose of atorvastatin followed 
by maintenance doses of at least 20 mg daily. Patients also 
received a loading dose of aspirin (325 mg PO) followed by 
a maintenance dose of 80 mg daily. At the end of the 12th 
week, hs-CRP was assessed again. Decision regarding the 
continuation of antiplatelet therapy at this time was made for 
each individual patient based on the guideline.
statistical analysis. All analyses were conducted by 
 Statistical Package for Social Sciences (SPSS) software, ver-
sion 21 (IBM Inc.). All data were initially analyzed using the 
Kolmogorov–Smirnov test to assess for normality. Quantita-
tive variables were presented as mean ± standard deviation 
(SD) for normally distributed variables and as median (inter-
quartile range, IQR) for variables without normal distribution. 
Categorical data were presented as numbers (percentages). The 
chi-square test was used for comparing the categorical data, 
and quantitative variables were compared by the Student’s 
t-test, the Mann–Whitney test, and the Kruskal–Wallis test, 
as appropriate. All P-values were two-tailed, and P , 0.05 
was considered statistically significant.
results
baseline and procedural characteristics. Of the 
120 patients randomized into the present study, 69 patients 
(57.5%) were male. All baseline characteristics were statis-
tically well matched between the treatment assignments, 
ie, prasugrel versus clopidogrel (Table 1). Although statisti-
cally nonsignificant, the prevalence of diabetes and the use of 
drug-eluting stents were considerably higher in the prasugrel 
group compared with the clopidogrel group. Pretreatment hs-
CRP level was also lower in the clopidogrel group (median, 
15.10 mg/dL; IQR, 9.62–23.75 mg/dL) compared with the 
prasugrel group on a borderline level of statistical significance 
(median, 18.00 mg/dL; IQR, 14.25–22.00 mg/dL; P = 0.06).
Associations of baseline hs-crP with the index event. 
Baseline median serum levels of hs-CRP were 15.00 mg/dL (IQR, 
7.50–18.50 mg/dL), 15.60 mg/dL (IQR, 11.87–22.00 mg/dL), 
23.00 mg/dL (IQR, 20.50–27.50 mg/dL), and 28.00 mg/L (IQR, 
22.00–42.50 mg/dL) in patients with elective, UA, NSTEMI, 
and STEMI index events, respectively; and these differences 
were statistically significant (Fig. 1, P , 0.001).
Association of baseline hs-crP with the index procedure. 
Patients who underwent single-vessel PCI had comparable baseline 
serum level of hs-CRP as compared with patients with multives-
sel PCI (median 18.00 mg/dL; IQR, 12.50–22.00 mg/dL versus 
median 17.00 mg/dL; IQR, 11.00–24.00 mg/dL; P = 0.07).
Association of baseline hs-crP with baseline charac-
teristics. Baseline hs-CRP is compared between different 
subgroups in both clopidogrel and prasugrel groups (Table 2). 
The results of multiple regression analysis indicated statisti-
cally significant relationships between baseline and index event 
(P , 0.001), beta blocker (P = 0.01), hypertension (P = 0.003), 
and statins (P = 0.01; Table 3).
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table 1. Baseline characteristics of the patients.
vaRIabLE CLoPIDogREL 
gRoUP
(n = 80) 
PRaSUgREL 
gRoUP
(n = 40)
P vaLUE
Clinical characteristics
age (yrs) 64 ± 9 63 ± 9 0.71
Male gender 48 (60) 21 (52.5) 0.43
Body mass index (kg/m2) 28.41 ± 4.51 27.64 ± 3.94 0.37
diabetes 24 (30) 25 (62.5) 0.41
hypertension 44 (55) 25 (62.5) 0.55
Current smoking 42 (52.5) 20 (50) 0.84
Clinical indication 
elective 34 (42.5) 16 (40) 0.40
Ua 28 (35) 12 (30)
nsteMi 10 (12.5) 7 (17.5)
steMi 8 (10) 5 (12.5)
Procedural characteristics 
one-vessel PCi 22 (27.5) 14 (35) 0.40
Multi-vessel PCi 58 (72.5) 26 (65)
Stent placement 
PoBa 14 (17.5) 7 (17.5) 0.80
Bare metal 56 (70) 20 (50)
drug-eluting 10 (12.5) 13 (32.5)
medications 
Beta blockers 38 (47.5) 21 (52.5) 0.69
aCe inhibitors 36 (45) 19 (47.5) 0.55
statins 54 (57.5) 24 (60) 0.42
Calcium channel blocker 24 (30) 14 (35) 0.67
notes: data are shown as mean (±sd) for continuous variables and numbers 
(percentage) for dichotomous variables.
abbreviations: aCe, angiotensin converting enzyme; nsteMi, non-st 
segment elevation myocardial infarction; steMi, st segment elevation 
myocardial infarction; PCi, percutaneous coronary intervention; PoBa, plain 
old balloon angioplasty; Ua, unstable angina.
effects of clopidogrel on hs-crP. Patients taking 
clopidogrel showed a significant reduction in hs-CRP level 
as compared with the baseline values (P , 0.001). Clopi-
dogrel decreased the median hs-CRP level from 15.10 mg/dL 
(9.62–23.75) to 8.50 mg/dL (6.00–10.75; P , 0.001). The 
effects of clopidogrel on hs-CRP levels in different subgroups 
are shown in Table 2.
effects of prasugrel on hs-crP. Prasugrel adminis-
tration also resulted in a significant reduction in hs-CRP 
level from 18.00 mg/dL (14.25–22.00) to 5.00 (3.00–5.00; 
P , 0.001). The effects of prasugrel on hs-CRP levels in dif-
ferent subgroups are demonstrated in Table 2.
Prasugrel compared with clopidogrel. A significant 
73% overall reduction in the primary end point (reduction in 
hs-CRP) was seen with prasugrel compared with 39% overall 
reduction in hs-CRP level with clopidogrel (Fig. 2, P = 0.002). 
In all subgroups, the hs-CRP reduction was  significantly 
higher in the prasugrel group compared with the clopidogrel 
group (Table 2).
discussion
The results of this study should be discussed in three 
main steps.
First, our data showed that baseline hs-CRP levels (prior 
PCI) were significantly different in patients with various types 
of index events. Patients with more advanced atherosclerosis 
event were more likely to have higher baseline hs-CRP (Fig. 1). 
We have demonstrated a similar finding in our previous study 
on 650 patients undergoing PCI.14 Moreover, according to our 
previous report,14 patients who undergo multivessel PCI have 
higher hs-CRP levels compared with patients with one- vessel 
PCI. However, in the present study, patients undergoing 
one-vessel PCI and multivessel PCI had comparable baseline 
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figure 1. the baseline hs-CrP level in patients with various index 
events before percutaneous coronary intervention.
abbreviations: Ua, unstable angina; nsteMi, non-st segment 
elevation myocardial infarction; steMi, st segment elevation 
myocardial infarction.
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hs-CRP, which may be due to our lower sample size in the 
present study. In addition, on multiple regression analysis, 
less serious index events, use of beta blockers and statins, and 
absence of hypertension were independently associated with 
lower baseline hs-CRP.
Second, we compared the changes in the hs-CRP 
 levels following the administration of prasugrel and clopi-
dogrel for 12 weeks. The main finding of the present study 
on 120 patients is that a 12-week administration of prasugrel 
to patients undergoing percutaneous coronary artery interven-
tion results in a significantly higher decrease in serum levels of 
hs-CRP as compared with clopidogrel.
Third, we performed extensive subgroup analyses to 
characterize patients who may have higher anti- inflammatory 
 benefits from either clopidogrel or prasugrel therapy. As 
patients within each subgroups were not well matched accord-
ing to their baseline hs-CRP values, we sought that the 
assessment of net difference values might be misleading, ie, 
patients with lower baseline hs-CRP levels might have lower 
difference in their hs-CRP level with therapy. As a result, we 
compared the percent of change in hs-CRP levels relative to 
the baseline values over the study period. Using this report-
ing strategy, we showed 73% reduction in the hs-CRP level 
with prasugrel compared with 39% reduction in hs-CRP 
level with clopidogrel, this difference was statistically signifi-
cant. According to Table 2, in both clopidogrel and prasugrel 
groups, male and female patients had comparable reduction in 
hs-CRP level. In the clopidogrel group, nondiabetic patients 
had approximately two times higher decrease in hs-CRP level 
compared with diabetic patients (50% versus 25%). In the pra-
sugrel group, diabetic and nondiabetic patients have statisti-
cally comparable reduction in hs-CRP level (66% versus 74%). 
This finding shows that anti-inflammatory effects of clopi-
dogrel is less prominent in diabetic patients, while prasugrel 
has comparable anti-inflammatory effects in both diabetics 
and nondiabetics. However, the pathophysiologic etiologies of 
these findings are not clear. Notably, the TRITON-TIMI 38 
trial demonstrated that administration of prasugrel to patients 
with DM have a greater reduction in ischemic events without 
an increase in TIMI major bleeding.15 They concluded that 
the more intensive oral antiplatelet therapy with prasugrel is 
associated with more benefit to DM patients.
However, our results demonstrate that hypertension and 
current smoking did not modify anti-inflammatory proper-
ties of clopidogrel and prasugrel. Moreover, there were no 
significant interactions between anti-inflammatory effects 
of clopidogrel or prasugrel and the index event prior to PCI. 
Interestingly, in the clopidogrel group, patients who have 
undergone multivessel PCI had significantly lower decrease in 
hs-CRP level compared to those with single-vessel PCI (33% 
versus 64%). Stent implantation and its type also could affect 
the anti-inflammatory effects of clopidogrel.
Platelet–leukocyte interactions are suggested to induce 
pro-inflammatory effects. Thus, it can be presumed that 
platelet inhibition by antiplatelets may also induce some 
anti-inflammatory properties. Some previous studies have 
demonstrated anti-inflammatory properties of clopidogrel. 
It has been shown that ADP-induced P-selectin expression 
and platelet–leukocyte conjugate formation can be inhibited 
by clopidogrel, but not by aspirin.16,17 Vivekananthan et al 
showed that clopidogrel treatment attenuated the periproce-
dural increase in CRP by 65%.18 Quinn et al also showed that 
clopidogrel pretreatment in patients undergoing PCI reduced 
inflammatory markers expression on platelets.19 However, 
such data regarding prasugrel are still lacking.
The TRITON-TIMI 38 trial demonstrated a significant 
reduction in primary end point in patients randomized to pra-
sugrel compared with those who received clopidogrel.12 In the 
PRASFIT-ACS study by Saito et al, efficacy and safety of 
prasugrel was compared with clopidogrel in Japanese patients 
with acute coronary syndrome.20 The primary efficacy end 
point was the incidence of major adverse cardiovascular events 
at 24 weeks, defined as a composite of cardiovascular death, 
nonfatal myocardial infarction, and nonfatal ischemic stroke. 
They showed that prasugrel with a loading dose of 20 mg and 
a maintenance dose of 3.75 mg was associated with a lower 
incidence of ischemic events compared with clopidogrel (9.4% 
versus 11.8%). According to their results, the incidence of 
noncoronary artery bypass graft-related major bleeding was 
similar in both groups. However, in none of these studies, 
table 3. Multiple regression model*.
moDEL UnStanDaRDIzED  
CoEffICIEntS
StanDaRDIzED 
CoEffICIEntS
P vaLUE 95% ConfIDEnCE  
IntERvaL foR b
b StD.  
ERRoR
bEta LowER boUnD UPPER 
boUnD
(Constant) 1.758 3.788 0.643 −5.745 9.261
index event 5.471 1.024 0.420 0.000 3.443 7.499
Beta blocker 4.782 1.826 0.203 0.010 1.165 8.398
hypertension −5.044 1.687 −0.212 0.003 −8.384 −1.703
statin 4.739 1.982 0.192 0.018 0.813 8.665
notes: *dependent variable: baseline hs-CrP.
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inflammatory markers of atherosclerosis such as hs-CRP were 
not assessed.
study limitations
The main limitation of this study was the relatively small 
sample size. Our results would be more conclusive if we had 
measured platelet inflammatory markers such as CD40 ligand 
and P-selectin. The relationship between anti-inflammatory 
and antiplatelet properties of clopidogrel and prasugrel would 
also been more clarified if we could measure in vitro antiplate-
let activity of these medications in each patient. The clinical 
importance of hs-CRP reduction would also been elucidated if 
we could include a clinical end point (eg, reduction in ischemic 
events) to our laboratory hs-CRP end point. Also the safety 
measures of prasugrel versus clopidogrel (eg, bleeding risk) 
have not been assessed in the current study.
As a result, future large-scale clinical trials overcoming 
the above limitations are suggested to make more comprehen-
sive comparisons between prasugrel and clopidogrel.
conclusion
In conclusion, prasugrel seems to be superior to clopidogrel 
in the reduction of hs-CRP in patients undergoing PCI, as 
it provides more uniform decrease in hs-CRP in different 
subgroups of patients. This may be related to higher inter-
individual variability in response to clopidogrel compared 
with prasugrel (due to their metabolism) and also the higher 
potency, better bioavailability, and lower pharmacodynamic 
variability of prasugrel.
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